Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

AfBPP of pyrrolopyrimidine α-helix mimetics

ABSTRACT: A wide range of small molecule scaffolds capable of mimicking protein α-helices to modulate protein-protein interactions have been reported, yet their target selectivity is poorly understood. Here, we report the affinity-based protein profiling of three structurally distinct classes of α-helix mimetics, N-substituted oligobenzamides, pyrrolopyrimidines, and oxopiperazines, all reported to inhibit the interaction between the tumour suppressor protein p53 and its negative regulator murine double minute 2 (MDM2).

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Amrita Date

LAB HEAD: Anna Barnard

PROVIDER: PXD063432 | Pride | 2026-08-05

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	AD_MS_043_PP2_A_S3-F2_1_5295.d.zip	Other
	AD_MS_043_PP2_B_S3-F5_1_5298.d.zip	Other
	AD_MS_043_PP2_C_S3-F8_1_5301.d.zip	Other
	AD_MS_043_PP2_D_S3-F11_1_5304.d.zip	Other
	AD_MS_043_PP2_PP_A_S3-F3_1_5296.d.zip	Other

Items per page:

1 - 5 of 16

Similar Datasets

AfBPP of oxopiperazine α-helix mimetics

Project description:A wide range of small molecule scaffolds capable of mimicking protein α-helices to modulate protein-protein interactions have been reported, yet their target selectivity is poorly understood. Here, we report the affinity-based protein profiling of three structurally distinct classes of α-helix mimetics, N-substituted oligobenzamides, pyrrolopyrimidines, and oxopiperazines, all reported to inhibit the interaction between the tumour suppressor protein p53 and its negative regulator murine double minute 2 (MDM2).

2026-08-05 | PXD063387 | Pride

AfBPP of N-substituted oligobenzamide α-helix mimetics

2026-08-05 | PXD063390 | Pride

AfBPP of α-helix mimetics in SJSA-1 cells

2026-08-05 | PXD063384 | Pride

Whole proteome characterisation following treatment with α-helix mimetic inhibitors of MDM2

Project description:A wide range of small molecule scaffolds capable of mimicking protein α-helices to modulate protein-protein interactions have been reported, yet their target selectivity is poorly understood. Here, we report the changes to the whole protoeme of SJSA-1 osteosarcoma cells following treatment with three structurally distinct classes of α-helix mimetics, N-substituted oligobenzamides, pyrrolopyrimidines, and oxopiperazines, all reported to inhibit the interaction between the tumour suppressor protein p53 and its negative regulator murine double minute 2 (MDM2).

2026-08-05 | PXD063398 | Pride

AfBPP of Navtemadlin probes in MCF-7 cells

Project description:Navtemadlin is a potent small moeclule inhibitor of the p53-MDM2 protein-protein interaction, that is being tested in Phase II/III clinical trials for the treatment of cancer. The selectivity of this molecule is poorly understood. So we synthesised and validated two photoactivatable clickable probes of Navtemadlin. This data shows the proteins enriched upon treatment of MCF-7 cells with these probes.

2025-04-28 | PXD058036 | Pride

AfBPP of Navtemadlin probes in SJSA-1 cells

2025-04-28 | PXD058033 | Pride

Optimised Sample Handling Minimises Peptide Adsorption to Plastics to Enable High Sensitivity Evosep Based Chemical Proteomics

Project description:Chemical proteomics approaches often yield low peptide recovery because they aim to enrich low-abundance proteins. Poor sample handling further reduces recovery through peptide adsorption to plastic surfaces and losses due to vacuum evaporation. We systematically mapped these losses across buffers, volumes, plastics and pH, then developed an Evotip-compatible handling protocol that minimises adsorption and removes the need for vacuum evaporation. Losses to plastic adsorption and vacuum evaporation were most apparent at low inputs (< 200 ng) and with larger volumes (> 20 µL) but were also dependent on acidification as well as the buffer and plastic used. The optimised workflow: direct acidification of peptides, frozen storage if needed, and direct loading onto Evotips, resulted in up to ~100-fold gains versus common drying practices. This optimised sample handling method enables high-throughput chemical proteomics by reducing manual handling steps and enables the characterisation of low abundance proteins previously lost during sample preparation.

2026-06-23 | PXD069322 | Pride

Establishment of Minimum Protein Standards for Mycobacterium tuberculosis-Derived Extracellular Vesicles through Comparison of EV Enrichment Methods

Project description:Extracellular vesicles (EVs) produced by Mycobacterium tuberculosis, the causative agent of tuberculosis, are involved in acquiring nutrients, evading host immune mechanisms, and modulating the host immune response. The functions of these M. tuberculosis EVs (MEVs)are hypothesized to be due to the dynamic composition of MEVs. However, there are various methods used to purify MEVs, and these methods can impact MEV characteristics such as size, purity, integrity, and composition. In this study, we investigated several methods for MEV purification, including: ultracentrifugation, differential density gradient-based ultracentrifugation, qEV size exclusion chromatography, and Capto(TM)Core size exclusion chromatography. We evaluated the size, concentration, appearance, purity, and protein composition (by mass spectrometry) of MEVs from each of these methods. We ultimately found that protein and particle yield vary across methods and that the size exclusion chromatography-based methods are more technically reproducible than the ultracentrifugation-based methods. Through mass spectrometry analysis, we also identified seven M. tuberculosis proteins that were present regardless of MEV enrichment method, that we propose could be used as qualitative markers of MEVs versus contaminants (in addition to MEV size and appearance criteria), to benefit the reproducibility of ongoing MEV studies.

2025-05-07 | PXD056465 | Pride

Utilization of Stability-based Proteomics for the Investigation of Structured RNA-protein Interactions

Project description:The stability of proteins from rates of oxidation (SPROX), thermal protein profiling (TPP) methods as well as triple helix pulldowns with LC-MS/MS readouts are used to identify the protein targets of three RNA ligands, the MALAT1 triple helix (TH), a viral stem loop (SL), and an unstructured RNA (PolyU) in LNCaP nuclear lysate. This work establishes a novel platform for the global discovery and interrogation of RNA-protein interactions that is generalizable to numerous biological contexts and RNA targets.

2024-01-31 | PXD043878 | Pride

Large-scale Proteomics Profiling of Peripheral Blood of DM1 patients identifies biomarkers for disease severity and physical activity - Validation cohort

Project description:Myotonic Dystrophy type 1 (DM1) is a progressive multisystem disease with large heterogeneity in disease onset, symptom development, progression rates and severity. This poses significant challenges to the design of clinical trials. To overcome some of these challenges, this study aims to identify protein biomarkers in serum that can serve as measures of therapy response. Biomarker discovery was performed in serum samples of DM1 patients in the OPTIMISTIC trial, which is deposited elsewhere. The dataset in this project comprises data generated on the Canadian cohort of DM1 patients which was used as external validation cohort.

2026-01-19 | PXD060035 | Pride